{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:27:05Z","timestamp":1793320025120,"version":"4.5.0"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0201371","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T14:27:33Z","timestamp":1533220053000},"page":"e0201371","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2248-9524","authenticated-orcid":true,"given":"Giovanni","family":"Ostuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angela","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0936-2908","authenticated-orcid":true,"given":"Federico","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Aguglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bortolaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-9988","authenticated-orcid":true,"given":"Camilla","family":"Callegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarita","family":"Caroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-799X","authenticated-orcid":true,"given":"Armando","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gastaldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lucii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Magliocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Nos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-0832","authenticated-orcid":true,"given":"Edoardo Giuseppe","family":"Ostinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8593","authenticated-orcid":true,"given":"Davide","family":"Papola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Piero","family":"Piccinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Purgato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tabacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Turrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the STAR Network Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1017\/S0033291703008328","article-title":"How often do patients with psychosis fail to adhere to treatment programmes? A systematic review","volume":"33","author":"M Nos\u00e9","year":"2003","journal-title":"Psychol Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"H Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/13651500600973568","article-title":"Partial compliance with antipsychotics and its impact on patient outcomes","volume":"11","author":"M Narasimhan","year":"2007","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"D Novick","year":"2010","journal-title":"Psychiatry Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2016.01.046","article-title":"Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)","volume":"172","author":"K Landolt","year":"2016","journal-title":"Schizophr Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia","volume":"74","author":"J Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref7","article-title":"Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review","author":"M Bowtell","year":"2017","journal-title":"Schizophr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders. A 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"CLM Hui","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"C Leucht","year":"2011","journal-title":"Schizophr. Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"T Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"T Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"S Brissos","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/15748847113089990057","article-title":"History and therapeutic rationale of long acting antipsychotics","volume":"9","author":"A de Risio","year":"2014","journal-title":"Curr Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1192\/bjp.195.52.s43","article-title":"Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review","volume":"52","author":"L Waddell","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1176\/ps.2007.58.4.482","article-title":"Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia","volume":"58","author":"L Shi","year":"2007","journal-title":"Psychiatr Serv"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/NMD.0b013e31829829c4","article-title":"Clinicians&apos; attitudes toward the use of long-acting injectable antipsychotics","volume":"201","author":"L Samalin","year":"2013","journal-title":"J Nerv Ment Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S2045796016001025","article-title":"New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base","volume":"26","author":"G Ostuzzi","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"A Cipriani","year":"2011","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis","volume":"18","author":"X Zhou","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S1092852913001016","article-title":"Long-acting injectable antipsychotics: shall the last be first","volume":"19","author":"SM Stahl","year":"2014","journal-title":"CNS Spectr"},{"key":"ref21","article-title":"Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia","author":"GL Stevens","year":"2016","journal-title":"Early Interv Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1192\/bjp.179.4.300","article-title":"Systematic review of patient and nurse attitudes to depot antipsychotic medication","volume":"179","author":"J Walburn","year":"2001","journal-title":"Br J Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1440-0979.2003.00277.x","article-title":"On the path to recovery: patients&apos; experiences of treatment with long-acting injections of antipsychotic medication","volume":"12","author":"B Svedberg","year":"2003","journal-title":"Int J Ment Health Nurs"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1192\/bjp.195.52.s1","article-title":"Antipsychotic long-acting injections: mind the gap","volume":"52","author":"MX Patel","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1177\/088740341305805s03","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives","volume":"58","author":"S Iyer","year":"2013","journal-title":"Can J Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2045125314542098","article-title":"A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections","volume":"4","author":"AK Das","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eurpsy.2016.05.008","article-title":"LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment","volume":"37","author":"F Pietrini","year":"2016","journal-title":"Eur Psychiatry"},{"key":"ref28","first-page":"917","article-title":"Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life","volume":"12","author":"C Montemagni","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2850.2010.01550.x","article-title":"Health professionals&apos; attitudes to depot injection antipsychotic medication: a systematic review","volume":"17","author":"C Besenius","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2045125312464106","article-title":"Patients&apos; and clinicians&apos; attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis","volume":"3","author":"M Kirschner","year":"2013","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1192\/apt.11.3.203","article-title":"Why aren&apos;t depot antipsychotics prescribed more often and what can be done about it","volume":"11","author":"MX Patel","year":"2005","journal-title":"Advances in Psychiatric Treatment"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1590\/1516-4446-2013-3503","article-title":"Why we should use long-acting injectable antipsychotics more frequently","volume":"35","author":"JP Maia-de-Oliveira","year":"2013","journal-title":"Rev Bras Psiquiatr"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.4088\/JCP.14com09541","article-title":"Long-acting injectable antipsychotics: an underutilized treatment option","volume":"75","author":"S Heres","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamapsychiatry.2015.0485","article-title":"Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia","volume":"72","author":"WT Carpenter","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"TRE Barnes","year":"2011","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref36","article-title":"A national clinical guideline","year":"2013"},{"key":"ref37","unstructured":"NICE. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]; 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.nice.org.uk\/guidance\/cg178\" xlink:type=\"simple\">https:\/\/www.nice.org.uk\/guidance\/cg178<\/ext-link>."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"C Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11414-013-9329-z","article-title":"Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia","volume":"40","author":"J Lin","year":"2013","journal-title":"J Behav Health Serv Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"754","DOI":"10.18553\/jmcp.2015.21.9.754","article-title":"Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge","volume":"21","author":"SC Marcus","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.16m02005","article-title":"Long-Acting Injectable Antipsychotics for Schizophrenia: Sociodemographic Characteristics and Treatment Adherence","volume":"19","author":"J McCreath","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/PPA.S127623","article-title":"Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic","volume":"11","author":"D Pilon","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.16m02044","article-title":"Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Spanish Province of Tarragona Catchment Area","volume":"19","author":"AM Gaviria","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/JCP.0000000000000755","article-title":"Evaluation of Concurrent Oral and Long-Acting Injectable Antipsychotic Prescribing at the Minneapolis Veterans Affairs Health Care System","volume":"37","author":"E Dimitropoulos","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e0179049","DOI":"10.1371\/journal.pone.0179049","article-title":"Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study","volume":"12","author":"F Decuypere","year":"2017","journal-title":"PLoS ONE"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JCP.0b013e318296884f","article-title":"Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial","volume":"33","author":"A Cipriani","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/1756-0500-7-731","article-title":"Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial","volume":"7","author":"F Girlanda","year":"2014","journal-title":"BMC Res Notes"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1017\/S2045796015000906","article-title":"Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study","volume":"25","author":"M Nos\u00e8","year":"2016","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"E von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"ref50","first-page":"67","article-title":"Psychological Measurements in Psychopharmacology","author":"JE Overall","year":"1974"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/S1121189X00006060","article-title":"Validazione della versione italiana della self-report Insight Scale","volume":"12","author":"R Roncone","year":"2003","journal-title":"Epidemiol Psichiatr Soc"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"S Leucht","year":"2005","journal-title":"Br J Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1037\/1040-3590.17.3.324","article-title":"Meta-analysis of the brief psychiatric rating scale factor structure","volume":"17","author":"A Shafer","year":"2005","journal-title":"Psychol Assess"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"TP Hogan","year":"1983","journal-title":"Psychol Med"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1121189X00005182","article-title":"Subjective response to neuroleptic medication. A validation study of the Italian version of the Drug Attitude Inventory (DAI)","volume":"10","author":"A Rossi","year":"2001","journal-title":"Epidemiol Psichiatr Soc"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/bmj.312.7027.345","article-title":"Compliance therapy in psychotic patients: randomised controlled trial","volume":"312","author":"R Kemp","year":"1996","journal-title":"BMJ"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"ref58","year":"2013"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/YIC.0b013e328303ac75","article-title":"Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages","volume":"23","author":"M Nos\u00e8","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"ref60","author":"JS Long","year":"2014"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.0006-341X.2000.00645.x","article-title":"A note on robust variance estimation for cluster-correlated data","volume":"56","author":"RL Williams","year":"2000","journal-title":"Biometrics"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1192\/bjp.195.52.s37","article-title":"Antipsychotic long-acting injections: prescribing practice in the UK","volume":"52","author":"TRE Barnes","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2010.02.1066","article-title":"Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities","volume":"119","author":"L Citrome","year":"2010","journal-title":"Schizophr Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-244X-11-168","article-title":"Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)","volume":"11","author":"C Crivera","year":"2011","journal-title":"BMC Psychiatry"},{"key":"ref65","author":"P Haddad","year":"2016"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials","volume":"196","author":"K Lieb","year":"2010","journal-title":"Br J Psychiatry"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"DT Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1176\/appi.ps.201500316","article-title":"Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012","volume":"67","author":"J Driessen","year":"2016","journal-title":"Psychiatr Serv"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2013.13040447","article-title":"Bipolar disorder, schizophrenia, and metabolic syndrome","volume":"170","author":"F Bartoli","year":"2013","journal-title":"Am J Psychiatry"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.genhosppsych.2014.08.005","article-title":"Cardiovascular risk factors among people with severe mental illness in Italy: a cross-sectional comparative study","volume":"36","author":"M Clerici","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"DA Regier","year":"1990","journal-title":"JAMA"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"AJ Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.comppsych.2014.11.021","article-title":"Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders: findings from the &quot;Psychiatric and Addictive Dual Disorder in Italy (PADDI)&quot; Study","volume":"58","author":"G Carr\u00e0","year":"2015","journal-title":"Compr Psychiatry"},{"key":"ref74","article-title":"Retrospective audit of people treated with long-acting antipsychotic injectable medications: Usage patterns and outcomes","author":"SJ Lee","year":"2017","journal-title":"Schizophr Res"},{"key":"ref75","first-page":"1","article-title":"Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder","author":"M Greene","year":"2017","journal-title":"J Med Econ"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia. A multiple-treatments meta-analysis","volume":"382","author":"S Leucht","year":"2013","journal-title":"The Lancet"},{"key":"ref77","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"P Khanna","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2016.11.010","article-title":"Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies","volume":"183","author":"G Ostuzzi","year":"2017","journal-title":"Schizophr Res"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-244X-13-155","article-title":"Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada","volume":"13","author":"L Lammers","year":"2013","journal-title":"BMC Psychiatry"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/schbul\/sbu128","article-title":"Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study","volume":"41","author":"J Nielsen","year":"2015","journal-title":"Schizophr Bull"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/2045125316632458","article-title":"Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability","volume":"6","author":"SM Singh","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia","volume":"52","author":"S Kapur","year":"2001","journal-title":"Annu Rev Med"},{"issue":"Suppl 4","key":"ref83","doi-asserted-by":"crossref","first-page":"377s","DOI":"10.1016\/S0924-9338(03)00077-4","article-title":"Current use of atypical antipsychotics","volume":"17","author":"F M\u00fcller-Spahn","year":"2002","journal-title":"Eur Psychiatry"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10401230490281410","article-title":"Atypical antipsychotics in the treatment of affective symptoms: a review","volume":"16","author":"PS Masan","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.1994.tb05827.x","article-title":"Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits","volume":"380","author":"NR Schooler","year":"1994","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"Suppl 1","key":"ref86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.13049su1c.01","article-title":"Developing concepts in negative symptoms: primary vs secondary and apathy vs expression","volume":"75","author":"B Kirkpatrick","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jpm.2008.9690","article-title":"Study design, precision, and validity in observational studies","volume":"12","author":"MDA Carlson","year":"2009","journal-title":"J Palliat Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0201371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T21:01:24Z","timestamp":1540242084000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0201371"}},"subtitle":[],"editor":[{"given":"Marianna","family":"Mazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":87,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0201371","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]}}}